“Research Use Only” in Canada: What the Label Means—and Does Not Mean
The short answer
“Research Use Only” communicates that a material is represented for laboratory research rather than personal or clinical use. In Canada, however, those words are not by themselves a market authorization, product classification decision or legal safe harbour.
Health Canada can consider the complete context: written and implied claims, product purpose, intended use, composition, form, surrounding educational or promotional material, and how the product is offered. A disclaimer cannot reliably cancel contradictory representations elsewhere.
Product classification depends on context
The Food and Drugs Act defines a drug partly by reference to how a substance is manufactured, sold or represented for use. Health Canada’s classification guidance emphasizes representations, purpose and intended use, composition and other product-specific factors.
Representations can be explicit or implicit. Names, images, claimed effects, comparisons, directions, linked articles and the placement or context of sale can contribute to the overall impression. Classification is case-specific.
What an RUO statement can communicate
An accurate RUO statement can make a research-only representation clear. It can help distinguish analytical or experimental discussion from a claim that a material is intended to diagnose, treat, prevent or cure a condition.
The statement should be consistent with the rest of the presentation. Personal-use directions, dosing schedules, injection guidance, therapeutic promises or consumer testimonials would conflict with a research-only representation.
What it does not establish
An RUO label does not establish that Health Canada reviewed or authorized the product. It does not prove safety, efficacy, quality, sterility, purity or suitability for use in humans. It does not automatically exempt a material from the Food and Drugs Act or the Food and Drug Regulations.
Health Canada’s device-specific RUO guidance illustrates the narrow nature of such labelling in that context: products represented for clinical diagnosis, clinical trials or other human use do not qualify simply because RUO words appear on the label. That medical-device guidance should not be treated as a peptide-specific exemption, but it reinforces the broader principle that stated purpose and actual representation must align.
Advertising and educational content
Under the Act, advertising includes representations made to promote a sale directly or indirectly. Health Canada’s guidance says promotional character is assessed from the message as a whole and the surrounding context, including linkages to related materials.
Scientific education is therefore not made non-promotional merely by being called a library article. Responsible educational content should separate published evidence from product claims, avoid purchase prompts inside scientific articles, identify evidence level and limitations, and avoid implying that findings for an authorized or investigational pharmaceutical transfer to a separately manufactured research material.
Unauthorized health-product claims
Health Canada states that only health products authorized for sale may be advertised as health products in Canada. The agency also warns that unauthorized health products have not been assessed for safety, efficacy and quality.
In July 2026, Health Canada announced a permanent injunction preventing Canlab Research and its representatives from selling unauthorized injectable peptides. The agency stated that selling unauthorized prescription drugs or making false or misleading treatment claims is illegal. This enforcement example is relevant context, but it does not decide the legal status of every differently presented material.
Reading evidence without creating a product claim
It is legitimate to discuss receptor biology, analytical chemistry, animal models and published clinical trials. The boundaries matter:
- identify the exact material and study type;
- distinguish laboratory, animal and human findings;
- do not translate mechanism into a promised outcome;
- do not treat evidence for one pharmaceutical as evidence for another material;
- avoid dosing, administration and personal-use instructions;
- keep scientific references separate from sales claims.
Key points
- “Research Use Only” is a representation of intended research purpose, not a Health Canada authorization.
- Canadian classification can consider claims, purpose, intended use, composition, form and surrounding context.
- Explicit and implicit representations both matter.
- A disclaimer cannot safely neutralize contradictory personal-use or therapeutic claims.
- Scientific education should remain evidence-led, non-instructional and clearly separated from product efficacy claims.
Important limitation
This article provides general educational information, not legal advice or a product-specific regulatory opinion. Canadian requirements and enforcement positions can change. A qualified Canadian regulatory professional or lawyer should assess any specific product, claim, label or commercial practice.
What this article does not establish
This article does not establish that any AURAPEP product has been reviewed, licensed, authorized, exempted or classified by Health Canada. It does not recommend any material for human or personal use.
References
- Government of Canada. Food and Drugs Act, section 2 definitions and sections 3 and 9. https://laws-lois.justice.gc.ca/eng/acts/f-27/fulltext.html
- Health Canada. Classification of products under the Food and Drugs Act. https://www.canada.ca/en/health-canada/services/drugs-health-products/classification-products-food-drugs-act.html
- Health Canada. Guidance on distinction between advertising and other activities. https://www.canada.ca/en/health-canada/services/drugs-health-products/regulatory-requirements-advertising/policies-guidance-documents/policy-distinction-between-advertising-activities.html
- Health Canada. Regulatory Requirements for Advertising. https://www.canada.ca/en/health-canada/services/drugs-health-products/regulatory-requirements-advertising.html
- Health Canada. COVID-19 tests for research use only. Device-specific guidance. https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/notice-research-use-only-labelling.html
- Health Canada. Health Canada obtains permanent injunction preventing Canlab Research’s illegal sale of injectable peptides in Canada. July 29, 2026. https://www.canada.ca/en/health-canada/news/2026/07/health-canada-obtains-permanent-injunction-preventing-canlab-researchs-illegal-sale-of-injectable-peptides-in-canada.html